Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid [3]

Inflammatory Bowel Diseases

Volumn 12, Issue 10, 2006, Pages 1007-1008

  Iemoli, Enrico ^a   Piconi, Stefania ^a   Ardizzone, Sandro ^a   Bianchi Porro, Gabriele ^a   Raimond, Fernando ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; AZATHIOPRINE; BALSALAZIDE; MESALAZINE; METHYLPREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE;

ANAMNESIS; CASE REPORT; ERYTHRODERMA; HUMAN; LABORATORY TEST; LETTER; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TOXIC EPIDERMAL NECROLYSIS;

COLITIS, ULCERATIVE; DERMATITIS, EXFOLIATIVE; EPIDERMAL NECROLYSIS, TOXIC; EXANTHEMA; HUMANS; MALE; MESALAMINE; SULFASALAZINE;

EID: 33749329749     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.mib.0000231569.43065.a4     Document Type: Letter

References (5)

1. Rouyeau J-C, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med. 1994;331:1272-1285.
2. Taffet SL, Das KM. Sulfasalazine: adverse effects and desensitization. Dig Dis Sci. 1983;28:833-843.
3. Giaffer MH, O'Briana CJ, Holdswort CD. Clinical tolerance to three 5-aminosalicilyc acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther. 1992;6:51.
4. McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther. 1988;2:237-243.
5. Mayers S, Sachar DB, Present DH, et al. Olsazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalizine. A prospective, randomized, placebo-controlled, double blind, dose-ranging clinical trial. Gastroenterology. 1987;93:1255.